Generex - Seriously?

I'm halfway surprised that Generex (Nasdaq: GNBT.OB) can still get anybody to listen to them. But I guess hope dies hard.

The company says that it has results from two "major" Phase 1 studies of Oral-lyn that ...

You know what? Forget it.

I'm not going to give this garbage pile any more of my time. Oral-lyn has been junk from day one and the notion that there is such a thing as a "major" Phase 1 study just proves all over again that this is a company that exists to suck up the capital of credulous retail investors.

Want to invest in a risky diabetes play? Go with Biodel (Nasdaq: BIOD) or MannKind (Nasdaq: MNKD). Go with Amylin (Nasdaq: AMLN), Novo Nordisk (NYSE: NVO), Insulet (Nasdaq: PODD) or DexCom (Nasdaq: DXCM) for something a little more tangible. Hell, take a flyer on Lexicon (Nasdaq: LXRX) and its early-stage diabetes compound.

But for god's sake, don't give Generex any more attention.

Disclosure: I own shares of Amylin and Lexicon